

Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

György Bodoky · Constanta Timcheva ·
David Robert Spigel · Phillip Joseph La Stella ·
Tudor Eliade Ciuleanu · G. Pover · N. C. Tebbutt

Published online: 26 July 2011
© Springer Science+Business Media, LLC 2011

Erratum to: Invest New Drugs
DOI 10.1007/s10637-011-9687-4

An error has occurred during production of this article. In Table 1 the published version states: selumetinib, $n=32$; capecitabine, $n=38$. This should be: selumetinib, $n=38$; capecitabine, $n=32$. The correct Table 1 is also shown on the next page.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s10637-011-9687-4>.

G. Bodoky (✉)
Department of Oncology, St. László Hospital,
Gyáli út 5-7,
1097 Budapest, Hungary
e-mail: bodokygy@hungarnet.hu

C. Timcheva
National Oncology Centre, Clinic of Chemotherapy,
5 Plovdivsko pole St.,
1756 Sofia, Bulgaria

D. R. Spigel
Sarah Cannon Research Institute, (SCRI),
250 25th Avenue North, Suite 110,
Nashville, TN 37203, USA

P. J. La Stella
St. Joseph Mercy Hospital Cancer Care Center,
5301 East Huron River Drive, P.O. Box 995,
Ann Arbor, MI 48106-0995, USA

T. E. Ciuleanu
Day Hospital Department-Medical Oncology,
Oncological Institute I Chiricuta,
Republicii 34-36 str,
Cluj-Napoca 40015, Romania

G. Pover
AstraZeneca,
Alderley Park, UK

N. C. Tebbutt
Austin Heath,
Heidelberg, VIC 3084, Australia

Table 1 Patient demographics and baseline characteristics (intent-to-treat population)

Characteristic	Number of patients (%)	
	Selumetinib <i>n</i> =38	Capecitabine <i>n</i> =32
Age (years)		
Mean (standard deviation)	63.1 (8.13)	62.0 (11.85)
Median (range)	65 (48–80)	62 (20–79)
Sex		
Male	24 (63)	11 (34)
Female	14 (37)	21 (66)
Race		
Caucasian	36 (95)	32 (100)
Oriental	2 (5)	0
Previous treatments		
Radiation	5 (13)	6 (19)
Surgery	29 (76)	25 (78)
Gemcitabine	38 (100)	32 (100)
Number of metastatic sites		
0	3 (8)	2 (6)
1	13 (34)	14 (44)
>1	22 (58)	16 (50)